Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
KangLaiTe USA
United States
- Ownership
- Private
- Development stage
- Other
01
Overview
KangLaiTe (KLT), developed by KangLaiTe USA and Zhejiang Kanglaite Pharmaceutical, is approved and marketed in China for cancer, cachexia, liver cancer, and non-small cell lung cancer, demonstrating efficacy as an adjunct to chemotherapy and targeted agents, with additional Phase II data in pancreatic and prostate cancer. Combination with EGFR-TKIs in advanced NSCLC improves response and immune function while maintaining safety, though benefits in EGFR-mutant disease remain uncertain and more studies are needed.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeHerbal medicineTraditional Chinese medicine
- Industry
- Biotech
Beyond the preview
Go deeper on KangLaiTe USA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KangLaiTe USA.